Promotion of liver regeneration and anti‑fibrotic effects of the TGF‑β receptor kinase inhibitor galunisertib in CCl4‑treated mice

Atsutaka Masuda(Kurume University), Takuji Torimura(Omuta hospital), Hideki Iwamoto, Toshimitsu Tanaka(Kurume University), Hiroyuki Suzuki(Kurume University), Takahiko Sakaue(Kurume University), Hironori Koga(Kurume University), Mitsuhiko Abe(Kurume University), Tõru Nakamura
International Journal of Molecular Medicine
May 5, 2020
10.3892/ijmm.2020.4594
Cited by 34

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
|Liver International|2020|410